Real-World Association of SGLT2 Inhibitors with Mortality in Very Elderly Patients with HFrEF and CKD
Antonio José Bollas Becerra·J Tunon·Jorge Balaguer Germán·Carlos Rodríguez-López·José María Romero Otero·J A Esteban Chapel·Luis Nieto Roca·Mikel Taibo Urquía·Ana María Pello Lázaro·Marcelino Cortes Garcia
Background: Heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) are common in the growing population of elderly patients, yet little evidence specifically targeting this population exists. The purpose of this study is to analyze the effect of SGLT2 inhibition in this cohort. Methods: A single-center, real-world observational study was performed. Patients aged >75 with HFrEF and CKD and theoretical indication for sodium–glucose cotransporter 2 (SGLT2) inhibito